Microbial secondary metabolites represent a cornerstone of modern drug discovery due to their remarkable structural diversity and unparalleled spectrum of bioactivities. A novel compound, (Z)-5-hydroxy-3-methylpent-2-enamide (compound 1), was isolated from the secondary metabolites of Fusarium acuminatum Ellis & Everh, and its structure was elucidated through various spectroscopic analyses. Preliminary pharmacological evaluation revealed that compound 1 exhibited remarkable antibacterial activity and potent α-glucosidase inhibitory effects. Notably, its inhibitory efficacy against the Gram-negative strains Pseudomonas aeruginosa and Salmonella enteritidis surpassed that of the reference drug ampicillin sodium, with MIC values of 64 μg/mL and 16 μg/mL, respectively, demonstrating promising potential for antibacterial drug development. As a valuable microbial-derived resource, compound 1 provides important experimental foundations for the development of novel antibacterial agents and α-glucosidase inhibitors.
Liu et al. (Tue,) studied this question.